MR-HYPERPOLARISATION SCANNING WITH HYPERPOLARISED PYRUVATE (13C) IN PANCREATIC CANCER PATIENTS – A FEASIBILITY STUDY

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517358-86-00

Enrollment

Registered

2024-09-13

Start date

2024-09-13

Completion date

Unknown

Last updated

2025-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Cancer

Brief summary

C13-Pyruvate spectroscopy imaging generates spectroscopic parameters (quantitative data for lactate, pyruvate, arginine and HCO3-). These will be projected 07-07-22 Projektbeskrivelse: MR-hyperpolarization 8. Version. Page 25 into a high-resolution anatomical image. The quantitative numerical data will be given as ratios, e.g. lactate/pyruvate-ratio, which gives us the possibility to perform comparisons between non-tumor vs. tumor tissue and pre-chemo vs. post-chemo.

Interventions

DRUGHyperpolarized [1-13C]pyruvate

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
C13-Pyruvate spectroscopy imaging generates spectroscopic parameters (quantitative data for lactate, pyruvate, arginine and HCO3-). These will be projected 07-07-22 Projektbeskrivelse: MR-hyperpolarization 8. Version. Page 25 into a high-resolution anatomical image. The quantitative numerical data will be given as ratios, e.g. lactate/pyruvate-ratio, which gives us the possibility to perform comparisons between non-tumor vs. tumor tissue and pre-chemo vs. post-chemo.	—

Measure

Time frame

—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026